ClinicalTrials.gg
CompletedNCT00446199Updated May 6, 2015Results posted

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

A Phase 3 interventional study of 0.5mg DRSP / 0.5mg E2 (BAY86-4891) and 0.25mg DRSP / 0.5mg E2 (BAY86-4891) in Vasomotor Symptoms and Hot Flashes, sponsored by Bayer. Completed at 76 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
735
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
3rd of 13
735 · median 431
Started
2007
with 3 others
Phase 3
8 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
4 of 13
Bayer

Among the 13 studies testing estradiol in Hot Flashes, this one is the 3rd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 3, and was the 6th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.

Read the detailed description

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.

03

Conditions studied

  • Vasomotor Symptoms
  • Hot Flashes

Browse trials for

Keywords

  • Vasomotor symptom relief
  • Postmenopausal women
  • Severe to Moderate Vasomotor symptoms
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women >40 years of age experiencing a minimum of 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week

Exclusion criteria

Exclusion Criteria:

  • The usual exclusion criteria for hormone therapy apply
  • Intake of medications other than hormones affecting hot flushes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
735 participants (actual)

Study arms

  • Experimental
    0.5mg DRSP / 0.5mg E2 (BAY86-4891)

    One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

    Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)

  • Experimental
    0.25mg DRSP / 0.5mg E2 (BAY86-4891)

    One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

    Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)

  • Experimental
    Estradiol (E2 0.3mg)

    One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).

    Drug: Estradiol (E2 0.3mg)

  • Placebo comparator
    Placebo

    Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).

    Drug: Placebo

Interventions

  • Drug0.5mg DRSP / 0.5mg E2 (BAY86-4891)

    Drug pages: Drospirenone · Estradiol

    One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

  • Drug0.25mg DRSP / 0.5mg E2 (BAY86-4891)

    Drug pages: Drospirenone · Estradiol

    One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).

  • One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).

  • DrugPlacebo

    Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.

    Time frame: Baseline until 12 weeks of treatment

  2. Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.

    Time frame: Baseline until 4 weeks of treatment

  3. Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.

    Time frame: Baseline until 12 weeks of treatment

  4. Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.

    Time frame: Baseline until 4 weeks of treatment

Secondary outcomes

  1. Change From Baseline to Week 12 in Vaginal pH

    Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.

    Time frame: Baseline until 12 weeks of treatment

  2. Change From Baseline to Week 12 in Vaginal Maturation Value

    Calculated as (percentage of superficial cells) + 0.5 \* (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.

    Time frame: Baseline until 12 weeks of treatment

  3. Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'

    Subjects self-assessed symptom severity

    Time frame: After 12 weeks of treatment

  4. Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'

    Subjects self-assessed symptom severity

    Time frame: After 12 weeks of treatment

  5. Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'

    Subjects self-assessed symptom severity

    Time frame: After 12 weeks of treatment

  6. Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'

    Subjects self-assessed symptom severity

    Time frame: After 12 weeks of treatment

  7. Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'

    Subjects self-assessed symptom severity

    Time frame: After 12 weeks of treatment

  8. Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'

    Subjects self-assessed presence or absence of symptom

    Time frame: After 12 weeks of treatment

  9. Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'

    Subjects self-assessed presence or absence of symptom

    Time frame: After 12 weeks of treatment

  10. Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'

    Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.

    Time frame: After 12 weeks of treatment

Other outcomes

  1. Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.

    Time frame: Baseline until 12 weeks of treatment

  2. Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.

    Time frame: Baseline until 4 weeks of treatment

  3. Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.

    Time frame: Baseline until 12 weeks of treatment

  4. Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

    Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.

    Time frame: Baseline until 4 weeks of treatment

07

Results

Posted Apr 18, 2012

Participant flow

The study was conducted at 79 centers in the United States from 26 Mar 2007 (date of first participant's first visit) to 03 Nov 2008 (date of last participant's last visit)

Participant flow — Overall Study
Milestone0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Started183184185183
Participants received treatment181183182180
Baseline and postdose vms data available178177179176
Completed160164158153
Not completed23202730
Withdrew: Adverse event7464
Withdrew: Lost to follow-up4526
Withdrew: Protocol violation1213
Withdrew: Withdrawal by subject25910
Withdrew: Site termination2001
Withdrew: Randomization in error2011
Withdrew: Lack of efficacy1001
Withdrew: Non-compliant with study drug1050
Withdrew: Non-compliant with visit schedule1112
Withdrew: Hormone fear0001
Withdrew: Lost interest in study participation0100
Withdrew: In-/exclusion criterion violated2121
Withdrew: Move0100

Outcome measures

PrimaryChange From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Median · Hot Flushes per week
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
Hot Flushes per week0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)-54.515 (-324.6 to 60.82)-54.125 (-215.9 to 9.03)-44.389 (-145.4 to 91.25)-30.020 (-485.3 to 55.91)
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = 0.0005 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
PrimaryChange From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.

Time frame:
Baseline until 4 weeks of treatment
Reported as:
Median · Hot Flushes per week
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
Hot Flushes per week0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)-46.868 (-276.63 to 60.82)-37.596 (-162.15 to 35.00)-31.621 (-141.44 to 37.91)-15.109 (-666.33 to 27.17)
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/ van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
PrimaryChange From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
Scores on a scale0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)-1.9294 (-3.000 to 0.480)-1.000 (-3.000 to 0.443)-0.2638 (-3.000 to 0.337)-0.0698 (-3.000 to 0.542)
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = 0.0096 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)stratification by center
PrimaryChange From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.

Time frame:
Baseline until 4 weeks of treatment
Reported as:
Median · Scorese on a scale
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
Scorese on a scale0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)-0.2905 (-3.000 to 0.383)-0.1821 (-2.800 to 1.267)-0.0651 (-2.898 to 0.380)0.0000 (-3.000 to 0.516)
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = 0.0005 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.)Stratification by center
SecondaryChange From Baseline to Week 12 in Vaginal pH

Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Mean · (pH)
Change From Baseline to Week 12 in Vaginal pH
(pH)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Vaginal pH-0.63 ± 0.874-0.63 ± 0.935-0.66 ± 0.967-0.06 ± 0.698
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = <0.0001Stratification by center
SecondaryChange From Baseline to Week 12 in Vaginal Maturation Value

Calculated as (percentage of superficial cells) + 0.5 \* (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Mean · Percentages of cells
Change From Baseline to Week 12 in Vaginal Maturation Value
Percentages of cells0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Vaginal Maturation Value10.07 ± 28.63811.71 ± 29.1857.69 ± 25.627-2.41 ± 20.923
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Wilcoxon/van Elteren · p = <0.0001Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Wilcoxon/van Elteren · p = <0.0001Stratification by center
SecondarySymptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'

Subjects self-assessed symptom severity

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
none83707170
mild59526247
moderate24382935
severe6111012
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0314 (no correction for multiplicity)stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.8780Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.5908Stratification by center
SecondarySymptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'

Subjects self-assessed symptom severity

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
none152140146128
mild20242122
moderate03511
severe0403
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0027 (no correction for multiplicity)Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.4463Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0303Stratification by center
SecondarySymptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'

Subjects self-assessed symptom severity

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
none166169167153
mild6219
moderate0010
severe0010
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.4397 (no correction for multiplicity)Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0132Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.3250Stratification by center
SecondarySymptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'

Subjects self-assessed symptom severity

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
none128132127118
mild21222119
moderate1371111
severe4434
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.9555 (no correction for multiplicity)Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.1743Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.4395Stratification by center
SecondarySymptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'

Subjects self-assessed symptom severity

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
none164162159151
mild2232
moderate0100
severe0000
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.8966 (no correction for multiplicity)Stratification by center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7512Stratification by center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.8751Stratification by center
SecondaryUrogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'

Subjects self-assessed presence or absence of symptom

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'45566257
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.1067Stratification for center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.6011Stratification for center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.4408Stratification for center
SecondaryUrogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'

Subjects self-assessed presence or absence of symptom

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'70535348
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0144Stratification for center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.5589Stratification for center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.5500Stratification for center
SecondaryUrogenital Symptoms: Number of Participants With Symptom 'Urination at Night'

Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.

Time frame:
After 12 weeks of treatment
Reported as:
Number · participants
Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'
participants0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'99114114111
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.2179Stratification for center
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7749Stratification for center
  • Estradiol (E2 0.3mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.8307Stratification for center
Other pre-specifiedChange From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Mean · Hot Flushes per week
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
Hot Flushes per week0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)-60.331 ± 37.5217-55.317 ± 30.2311-41.783 ± 32.6122-31.916 ± 44.4507
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -27.6 · 95% CI -33.2 to -22.0Change in active treatment arm minus change in placebo arm
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -22.2 · 95% CI -27.8 to -16.6Change in active treatment arm minus change in placebo arm
  • Estradiol (E2 0.3mg) vs Placebo · ANCOVA · p = 0.0007 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -9.8 · 95% CI -15.4 to -4.2Change in active treatment arm minus change in placebo arm
Other pre-specifiedChange From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.

Time frame:
Baseline until 4 weeks of treatment
Reported as:
Mean · Hot Flushes per week
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
Hot Flushes per week0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)-48.810 ± 35.7876-38.989 ± 27.7812-32.633 ± 28.1349-24.195 ± 54.7480
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -23.9 · 95% CI -29.9 to 17.8Change in active treatment arm minus change in placebo arm
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -14.2 · 95% CI -20.2 to -8.1Change in active treatment arm minus change in placebo arm
  • Estradiol (E2 0.3mg) vs Placebo · ANCOVA · p = 0.0054 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -8.6 · 95% CI -14.6 to -2.5Change in active treatment arm minus change in placebo arm
Other pre-specifiedChange From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.

Time frame:
Baseline until 12 weeks of treatment
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
Scores on a scale0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)-1.4473 ± 1.11616-1.2141 ± 1.08299-0.7822 ± 1.03497-0.3873 ± 0.76950
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -1.069 · 95% CI -1.280 to -0.859Change in active treatment arm minus change in placebo arm
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -0.803 · 95% CI -1.013 to -0.593Change in active treatment arm minus change in placebo arm
  • Estradiol (E2 0.3mg) vs Placebo · ANCOVA · p = 0.0007 (significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -0.361 · 95% CI -0.570 to -0.152Change in active treatment arm minus change in placebo arm
Other pre-specifiedChange From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.

Time frame:
Baseline until 4 weeks of treatment
Reported as:
Mean · scores on a scale
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
scores on a scale0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)-0.8347 ± 1.02226-0.5859 ± 0.89106-0.4033 ± 0.73774-0.1926 ± 0.63585
Statistical analysis
  • 0.5mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -0.635 · 95% CI -0.813 to -0.458Treatment, Center, and Baseline value used as covariate
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) vs Placebo · ANCOVA · p = <0.0001 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -0.382 · 95% CI -0.560 to -0.205Treatment, Center, and Baseline value used as covariate
  • Estradiol (E2 0.3mg) vs Placebo · ANCOVA · p = 0.0233 (Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.) · Mean difference (final values): -0.204 · 95% CI -0.381 to -0.028Treatment, Center, and Baseline value used as covariate

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5mg DRSP / 0.5mg E2 (BAY86-4891)—0/181 (0%)80/181 (44.2%)
0.25mg DRSP / 0.5mg E2 (BAY86-4891)—1/183 (0.5%)75/183 (41%)
Estradiol (E2 0.3mg)—3/182 (1.6%)68/182 (37.4%)
Placebo—1/180 (0.6%)64/180 (35.6%)
Most frequent serious events
Most frequent serious events
Event0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Road traffic accidentInjury, poisoning and procedural complications0/1810/1830/1821/180
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1810/1831/1820/180
Oropharyngeal cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1810/1831/1820/180
Ovarian cystReproductive system and breast disorders0/1810/1831/1820/180
Uterine polypReproductive system and breast disorders0/1810/1831/1820/180
SalpingitisInfections and infestations0/1811/1830/1820/180
Most frequent other events
Showing 10 of 31
Most frequent other events
Event0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)Placebo
Breast tendernessReproductive system and breast disorders12/1816/1831/1820/180
HeadacheNervous system disorders8/18111/18310/1829/180
Low density lipoprotein increasedInvestigations4/1817/1837/1829/180
Abdominal painGastrointestinal disorders2/1818/1835/1821/180
Cervical dysplasiaReproductive system and breast disorders2/1818/1835/1827/180
Vaginitis bacterialInfections and infestations7/1813/1837/1827/180
Pain in extremityMusculoskeletal and connective tissue disorders4/1814/1831/1827/180
Back painMusculoskeletal and connective tissue disorders7/1812/1834/1823/180
NasopharyngitisInfections and infestations4/1816/1834/1826/180
Upper respiratory tract infectionInfections and infestations6/1813/1834/1823/180

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)PlaceboTotal
Mean53.8 ± 5.6153.5 ± 5.7753.3 ± 6.0553.4 ± 6.4653.5 ± 5.97
Sex: Female, Male
Sex: Female, Male(Participants)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)PlaceboTotal
Female178177179176710
Male00000
Number of participants with hysterectomy/oophorectomy
Number of participants with hysterectomy/oophorectomy(Participants)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)PlaceboTotal
hysterectomized98919899386
oophorectomized61616359244
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/sqm)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)PlaceboTotal
Mean29.070 ± 6.063628.190 ± 5.696529.080 ± 5.741027.882 ± 5.785928.543 ± 5.8370
Years since last menstruation at baseline
Years since last menstruation at baseline(years)0.5mg DRSP / 0.5mg E2 (BAY86-4891)0.25mg DRSP / 0.5mg E2 (BAY86-4891)Estradiol (E2 0.3mg)PlaceboTotal
Mean9.913 ± 8.67198.784 ± 7.99479.214 ± 8.18929.509 ± 8.96939.355 ± 8.4560
08

Study locations

76 sites
  • Mobile, Alabama 36608, United States
  • Chandler, Arizona 85225, United States
  • Phoenix, Arizona 85031, United States
  • Tucson, Arizona 85712, United States
  • Tucson, Arizona 85741, United States
  • Little Rock, Arkansas 72205, United States
  • Paramount, California 90723, United States
  • San Diego, California 92103, United States
  • San Diego, California 92108, United States
  • San Diego, California 92121, United States
  • San Diego, California 92123, United States
  • Valley Village, California 91607, United States
  • Vista, California 92083, United States
  • Colorado Springs, Colorado 80910, United States
  • Denver, Colorado 80218, United States
  • New Britain, Connecticut 06050, United States
  • Boynton Beach, Florida 33437, United States
  • Clearwater, Florida 33761, United States
  • Daytona Beach, Florida 32114, United States
  • Fort Myers, Florida 33916, United States
  • Jacksonville, Florida 32216, United States
  • Lake Worth, Florida 33461, United States
  • Leesburg, Florida 34748, United States
  • Miami, Florida 33169, United States
  • Miami, Florida 33186, United States
  • New Port Richey, Florida 34655, United States
  • Tampa, Florida 33607, United States
  • West Palm Beach, Florida 33409, United States
  • Atlanta, Georgia 30328, United States
  • Atlanta, Georgia 30342, United States
  • Decatur, Georgia 30034, United States
  • Boise, Idaho 83702, United States
  • Idaho Falls, Idaho 83404, United States
  • Arlington Heights, Illinois 60004, United States
  • Champaign, Illinois 61820, United States
  • La Grange Park, Illinois 60526, United States
  • Newburgh, Indiana 47630, United States
  • Lexington, Kentucky 40536, United States
  • Amite, Louisiana 70422, United States
  • Marrero, Louisiana 70072, United States
  • Paw Paw, Michigan 49079, United States
  • Chaska, Minnesota 55318, United States
  • Springfield, Missouri 65802, United States
  • Billings, Montana 59101, United States
  • Billings, Montana 59102, United States
  • Lincoln, Nebraska 68510, United States
  • Las Vegas, Nevada 89104, United States
  • Reno, Nevada 89502, United States
  • Lawrenceville, New Jersey 08648, United States
  • New Brunswick, New Jersey 08901, United States
  • Princeton, New Jersey 08540, United States
  • Albuquerque, New Mexico 87102, United States
  • Raleigh, North Carolina 27612, United States
  • Winston-Salem, North Carolina 27103, United States
  • Fargo, North Dakota 58105, United States
  • Cleveland, Ohio 44122, United States
  • Columbus, Ohio 43213, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Tulsa, Oklahoma 74105, United States
  • Erie, Pennsylvania 16502, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Wexford, Pennsylvania 15090, United States
  • Columbia, South Carolina 29201, United States
  • Sioux Falls, South Dakota 57105, United States
  • Chattanooga, Tennessee 37403, United States
  • Chattanooga, Tennessee 37404, United States
  • Memphis, Tennessee 38120, United States
  • Dallas, Texas 75234, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77030, United States
  • Burlington, Vermont 05401, United States
  • Norfolk, Virginia 23507, United States
  • Richmond, Virginia 23294, United States
  • Renton, Washington 98055, United States
  • Seattle, Washington 98105, United States
09

References and documents

Publications

  • Sutter G, Schmelter T, Gude K, Schaefers M, Gerlinger C, Archer DF. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17beta-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. Menopause. 2014 Mar;21(3):236-42. doi: 10.1097/GME.0b013e31829c12e8. PubMed 23963309 ↗
  • Archer DF, Schmelter T, Schaefers M, Gerlinger C, Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17beta-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014 Mar;21(3):227-35. doi: 10.1097/GME.0b013e31829c1431. PubMed 23963307 ↗
  • K. Gude; T. Schmelter; M. Schaefers; C. Gerlinger. Efficacy of low dose Angeliq (0.5 mg E2 and 0.25 or 0.5 mg DRSP) compared to Angeliq (1 mg E2 and 1, 2 or 3 mg DRSP) in postmenopausal women with moderate to severe hot flushes. Menopause, Vol. 19, No. 12, 2012 * 2012, P-36, p 1388
  • Gerlinger C, Gude K, Hiemeyer F, Schmelter T, Schafers M. An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women. Menopause. 2012 Jul;19(7):799-803. doi: 10.1097/gme.0b013e31823de8ba. PubMed 22228322 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Oct 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 3 years 6 months after primary completion. A results delay was requested in Dec 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2007
First posted
Mar 12, 2007
Start
Mar 2007
Primary completionActual
Oct 2008
CompletionActual
Nov 2008
Results delay requested
Dec 10, 2009
Results first posted
Apr 18, 2012
Last update
May 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00446199
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 12, 2007
Start date
Mar 2007
Primary completion
Oct 2008
Completion
Nov 2008
Results posted
Apr 18, 2012
Last update
May 6, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drospirenone · Estradiol

Start the discussion